Trial Profile
A Phase 2 Study to Examine the Safety, Tolerability and Efficacy of APL-130277 in Patients With Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Apomorphine (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics; Proof of concept; Therapeutic Use
- Sponsors Cynapsus Therapeutics
- 19 Jul 2016 Results published in the Movement Disorders (2016).
- 21 Apr 2016 Results assessing safety of apomorphine presented at the 68th Annual Meeting of the American Academy of Neurology.
- 21 Apr 2016 Results (subgroup analysis) assessing effects of apomorphine on the rapid reversal of OFF episodes in PD presented at the 68th Annual Meeting of the American Academy of Neurology.